Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

Shares of Stemline Therapeutics (NASDAQ:STML) tumbled nearly 37%

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
guchu Member Profile
 
Followed By 3
Posts 453
Boards Moderated 0
Alias Born 02/23/16
160x600 placeholder
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Jap... GlobeNewswire Inc. - 10/8/2019 7:30:00 AM
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress GlobeNewswire Inc. - 10/1/2019 7:30:00 AM
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress GlobeNewswire Inc. - 9/27/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 4:01:00 PM
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 9:32:15 AM
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/5/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/9/2019 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 1:18:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/9/2019 1:16:29 PM
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock GlobeNewswire Inc. - 8/8/2019 10:23:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/8/2019 6:10:20 AM
Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc. - 8/7/2019 4:25:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:37:16 PM
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS® GlobeNewswire Inc. - 8/6/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2019 7:31:04 AM
Stemline Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019 GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its An... GlobeNewswire Inc. - 7/8/2019 5:50:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:18:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:09 PM
guchu   Friday, 02/03/17 09:01:42 AM
Re: None
Post # of 67 
Shares of Stemline Therapeutics (NASDAQ:STML) tumbled nearly 37% this morning after investors learned that a patient died in a clinical trial involving its lead drug candidate, SL-401. The news was not reported by the company, but confirmed by the patient's family and first reported by Adam Feuerstein of TheStreet.

Not hearing the news directly from management is bad enough, but the death occurred the day before a Jan. 19 stock offering for $45 million. Worse still, this is the third death to occur in a clinical trial involving SL-401 from a side effect known as capillary leak syndrome, a form of low blood pressure. The company had responded to previous patient deaths by altering dosing regimens, so the recent death hints that the drug may not be safe enough for human use in its current form or dosing.

Safety concerns now seem likely to derail an otherwise effective drug candidate -- an increasingly common theme for next-generation immunotherapy treatments. As Feuerstein writes, in earlier clinical trials "SL-401 has demonstrated robust overall tumor response rates of 84%, including 56% complete or near-complete response in patients enrolled in its clinical trial." The company had previously expected to use phase 2 results to obtain marketing approval for the drug candidate, but that now could be in doubt.

https://www.fool.com/investing/2017/02/02/heres-why-stemline-therapeutics-stock-fell-369-thi.aspx


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist